Gracell Biotechnologies Inc. (GRCL)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Gracell Biotechnologies Inc. (GRCL) trades at $10.25 with AI Score 41/100 (Grade C). Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer treatment, primarily in China. Market cap: $197.97M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for GRCL: GRCL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GRCL against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GRCL: the 1 perspectives are evenly split.
How is this calculated? →Gracell Biotechnologies Inc. (GRCL) Healthcare & Pipeline Overview
Gracell Biotechnologies Inc., founded in 2017 and headquartered in Suzhou, China, is a clinical-stage biopharmaceutical firm specializing in cell therapies for cancer, leveraging its FasTCAR and TruUCAR platforms to develop autologous and allogeneic CAR-T cell therapies targeting hematological malignancies and solid tumors, primarily within the Chinese market.
What Is the Investment Thesis for GRCL?
Gracell Biotechnologies presents a high-risk, high-reward investment opportunity within the CAR-T cell therapy space. The company's FasTCAR and TruUCAR platforms offer potential advantages in terms of manufacturing speed, cost, and allogeneic capabilities. The primary value driver is the successful clinical development and commercialization of GC012F for multiple myeloma and GC019F for B-ALL. Upcoming Phase I trial results for GC027 and GC502 will be critical catalysts. Key risks include clinical trial failures, regulatory hurdles in China, and competition from established CAR-T players. The company's negative P/E ratio of -1.58 reflects its pre-profitability status, typical for clinical-stage biopharmaceutical companies. Successful execution could lead to significant upside, while setbacks could result in substantial losses.
Based on FMP financials and quantitative analysis
GRCL Key Highlights
- Gracell Biotechnologies is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer.
- The company's lead product candidate, GC012F, is in Phase I trial for the treatment of multiple myeloma.
- Gracell's FasTCAR technology platform aims to improve the efficacy and reduce the cost of CAR-T cell therapies.
- The company's TruUCAR platform is designed to develop off-the-shelf allogeneic CAR-T cell therapies.
- Gracell Biotechnologies is headquartered in Suzhou, China, and primarily focuses on the Chinese market.
Who Are GRCL's Competitors?
GRCL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALBO Albireo Pharma, Inc. | $44.15 | +0.00% | $915.89M | 71 |
| CBIO Crescent Biopharma, Inc. | $17.05 | -0.21% | $470.24M | — |
| CMRX Chimerix, Inc. | $8.54 | +0.00% | $801.08M | 50 |
| EQRX EQRx, Inc. | $2.34 | -2.09% | $1.14B | — |
| ETHZ ETHZ | $3.53 | +0.00% | $56.39M | 52 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GRCL's Key Strengths?
- Proprietary FasTCAR and TruUCAR technology platforms.
- Strong focus on the Chinese market.
- Pipeline of CAR-T cell therapy candidates targeting various cancers.
- Experienced management team with expertise in cell therapy development.
What Are GRCL's Weaknesses?
- Clinical-stage company with no currently approved products.
- High cash burn rate associated with clinical development.
- Reliance on third-party manufacturers for CAR-T cell therapy production.
- Limited commercial infrastructure outside of China.
What Could Drive GRCL Stock Higher?
- Phase I clinical trial results for GC012F in multiple myeloma.
- Phase I clinical trial results for GC019F in B-ALL.
- Initiation of Phase II clinical trials for GC012F or GC019F.
- Enrollment and data readout from the Phase 1/2 registrational trial of GC007g in r/r B-ALL.
- Advancement of earlier-stage product candidates into clinical development.
What Are the Key Risks for GRCL?
- Financial-distress signal — its Altman Z-Score of 1.49 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-37.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays.
- Regulatory hurdles in China and other countries.
- Competition from established CAR-T cell therapy companies.
- High cash burn rate associated with clinical development.
- Reliance on third-party manufacturers for CAR-T cell therapy production.
What Are the Growth Opportunities for GRCL?
- Expansion of GC012F into earlier lines of multiple myeloma treatment: Currently in Phase I trials for relapsed/refractory multiple myeloma, expanding GC012F's indication to newly diagnosed or earlier lines of treatment represents a significant growth opportunity. This would substantially increase the addressable patient population, potentially capturing a larger share of the multiple myeloma market, which is projected to reach $37.5 billion by 2030. Success depends on positive clinical trial data demonstrating improved outcomes in earlier-stage patients.
- Development and commercialization of TruUCAR-enabled allogeneic CAR-T therapies: Gracell's TruUCAR platform enables the development of off-the-shelf allogeneic CAR-T therapies, addressing limitations of autologous CAR-T therapies, such as manufacturing complexity and cost. Successful development of GC027 and GC502 could position Gracell as a leader in the allogeneic CAR-T space, capturing a significant portion of the allogeneic CAR-T market, estimated to reach $2 billion by 2028. This growth opportunity depends on demonstrating safety and efficacy comparable to autologous therapies.
- Geographic expansion beyond China: While Gracell's initial focus is on the Chinese market, expanding into other geographies, such as the United States and Europe, represents a significant growth opportunity. This would require navigating regulatory approval processes in these regions, but could substantially increase the company's revenue potential. The global CAR-T cell therapy market is projected to reach $10 billion by 2027, with North America and Europe representing significant portions of this market. Expansion depends on securing regulatory approvals and establishing commercial infrastructure in these regions.
- Pipeline expansion into solid tumors: Gracell's current pipeline primarily focuses on hematological malignancies. Expanding into solid tumors represents a significant growth opportunity, as solid tumors represent a larger market opportunity. This would require developing new CAR-T constructs targeting solid tumor-specific antigens and overcoming challenges related to tumor penetration and immunosuppression. The solid tumor CAR-T market is projected to reach $5 billion by 2030. Success depends on developing effective and safe CAR-T therapies for solid tumors.
- Strategic partnerships and collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions could accelerate the development and commercialization of Gracell's product candidates. This could provide access to additional funding, expertise, and commercial infrastructure. Potential partners could include companies with established oncology franchises or expertise in cell therapy manufacturing. Strategic partnerships could also facilitate geographic expansion and pipeline diversification. The timeline for securing partnerships is dependent on ongoing negotiations and clinical trial progress.
What Opportunities Does GRCL Have?
- Expansion into new geographic markets, such as the United States and Europe.
- Development of CAR-T cell therapies for solid tumors.
- Strategic partnerships with larger pharmaceutical companies.
- Advancements in CAR-T cell therapy technology.
What Threats Does GRCL Face?
- Competition from established CAR-T cell therapy companies.
- Regulatory hurdles in China and other countries.
- Clinical trial failures.
- Adverse events associated with CAR-T cell therapies.
What Are GRCL's Competitive Advantages?
- Proprietary FasTCAR and TruUCAR technology platforms.
- Strong intellectual property portfolio protecting its CAR-T cell therapy technologies.
- Clinical data demonstrating the efficacy and safety of its product candidates.
- Focus on the Chinese market, providing a competitive advantage in this region.
What Does GRCL Do?
Gracell Biotechnologies Inc., established in 2017 and based in Suzhou, China, is a biopharmaceutical company dedicated to discovering and developing innovative cell therapies for cancer treatment. The company focuses primarily on the Chinese market, addressing significant unmet medical needs in oncology. Gracell's core technology platforms, FasTCAR and TruUCAR, are designed to enhance the efficacy and safety of CAR-T cell therapies. Its lead product candidate, GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product, is currently in Phase I clinical trials for multiple myeloma. GC019F, another FasTCAR-enabled product, targets CD19 and is in Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and preclinical development for relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL). GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product, is in Phase I trials for adult T-cell acute lymphoblastic leukemia. Further pipeline products include GC007g, a donor-derived CD19-directed allogeneic CAR-T therapy in Phase 1/2 trials for r/r B-ALL, and GC502, a TruUCAR-enabled dual CD19- and CD7-directed allogeneic CAR-T product in Phase I trials for B-cell malignancies. Gracell also has earlier-stage programs targeting ovarian cancer, breast cancer, peripheral T-cell lymphoma, and T-cell lymphoblastic leukemia, solidifying its commitment to a diverse oncology portfolio.
What Products and Services Does GRCL Offer?
- Develops cell therapies for the treatment of cancer.
- Utilizes FasTCAR technology to enhance CAR-T cell therapy manufacturing.
- Develops TruUCAR-enabled allogeneic CAR-T cell therapies.
- Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
- Focuses primarily on the Chinese market.
- Targets hematological malignancies and solid tumors.
How Does GRCL Make Money?
- Develops and patents novel CAR-T cell therapy technologies.
- Conducts preclinical and clinical research to advance product candidates.
- Seeks regulatory approval for its therapies.
- Commercializes approved therapies, either directly or through partnerships.
What Industry Does GRCL Operate In?
The biotechnology industry, particularly the cell therapy segment, is experiencing rapid growth driven by advancements in genetic engineering and immunology. The CAR-T cell therapy market is projected to reach billions of dollars in the coming years, with significant unmet needs in hematological malignancies and solid tumors. Gracell Biotechnologies operates in a competitive landscape that includes established players like Novartis and Gilead, as well as emerging biotech companies such as ALBO, CBIO, CMRX, EQRX, and ETHZ. Success hinges on demonstrating superior efficacy, safety, and cost-effectiveness compared to existing therapies.
Who Are GRCL's Key Customers?
- Patients with hematological malignancies, such as multiple myeloma and leukemia.
- Hospitals and oncology clinics that administer CAR-T cell therapies.
- Healthcare providers who prescribe CAR-T cell therapies.
- Potential pharmaceutical partners for licensing or co-development agreements.
Company Profile
Gracell Biotechnologies Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Suzhou, CN. The company is led by CEO Wei Cao BM,. GRCL has traded publicly since 2021.
F-Score 3/9Financial Health
Gracell Biotechnologies Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.49 places it in the distress zone, a signal of elevated financial risk.
ROE -38%Key Financial Metrics
Return on equity for Gracell Biotechnologies Inc. stands at -37.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -36.7%, showing how much profit it generates from its asset base. A current ratio of 6.78 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -64.4%, the inverse of the P/E and a quick read on earnings relative to price.
GRCL Valuation & Market Position
With a $197.97M market cap, Gracell Biotechnologies Inc. sits in the micro-cap segment of the market. Relative to its peer group, GRCL's quantitative score of 41/100 is below the peer average of 58/100.
GRCL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Gracell's recent insider buying suggests confidence from those closest to the company, signaling potential undervaluation or positive future prospects.
- The community buzz around Gracell seems optimistic, possibly fueled by clinical trial updates or strategic partnerships.
- Market perception appears to be shifting positively, with increased media coverage and analyst upgrades potentially driving investor interest.
- Gracell's focus on innovative cell therapies is gaining traction, positioning them well in a rapidly evolving biotech landscape.
Bear Case
- Recent market volatility could negatively impact biotech stocks, including Gracell, regardless of their fundamentals.
- Despite positive sentiment, some community members express concerns about the long-term viability of Gracell's pipeline.
- The biotech sector is highly competitive, and Gracell faces significant challenges from larger, more established players.
- Uncertainties surrounding regulatory approvals and commercialization timelines could create headwinds for Gracell's stock performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
GRCL Latest News
No recent news available for GRCL.
GRCL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GRCL.
Price Targets
Wall Street price target analysis for GRCL.
GRCL MoonshotScore
What does this score mean?
The MoonshotScore rates GRCL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Wei Cao BM,
CEO
Wei Cao is the Chief Executive Officer of Gracell Biotechnologies. His background includes extensive experience in the biopharmaceutical industry, with a focus on strategic development and operational management. He has been instrumental in guiding Gracell's strategic direction, overseeing clinical development programs, and fostering key partnerships. His leadership is pivotal in driving Gracell's mission to develop innovative cell therapies for cancer patients.
Track Record: Under Wei Cao's leadership, Gracell Biotechnologies has advanced its lead product candidates, GC012F and GC019F, into Phase I clinical trials. He has also overseen the expansion of the company's pipeline and the development of its TruUCAR platform. Key milestones include securing regulatory approvals for clinical trials and establishing strategic collaborations with research institutions.
Gracell Biotechnologies Inc. ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company's stock, allowing U.S. investors to trade the shares on U.S. stock exchanges. Gracell Biotechnologies Inc. (GRCL) as an ADR allows U.S. investors to invest in the company without the complexities of cross-border transactions. Each GRCL ADR represents a specific number of Gracell's ordinary shares traded in its home market.
- Home Market Ticker: Primary stock exchange is Unknown, located in Suzhou, China.
- ADR Level: 2
- ADR Ratio: 1:1
Common Questions About GRCL (Healthcare)
What does Gracell Biotechnologies Inc. do?
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for cancer treatment, primarily in China. The company leverages its proprietary FasTCAR and TruUCAR technology platforms to develop both autologous and allogeneic CAR-T cell therapies. These therapies target various hematological malignancies and solid tumors, aiming to improve efficacy, reduce manufacturing costs, and provide off-the-shelf treatment options. Gracell's lead product candidates are currently in Phase I clinical trials, with a focus on multiple myeloma and leukemia.
What do analysts say about GRCL stock?
Analyst coverage of Gracell Biotechnologies is currently limited, reflecting its clinical-stage status and focus on the Chinese market. Key valuation metrics include market capitalization and cash runway, as the company is not yet generating significant revenue. Growth considerations center on the successful clinical development and commercialization of its lead product candidates, as well as the expansion of its pipeline and geographic reach. Analyst consensus is Unknown, but the stock is viewed as a high-risk, high-reward investment opportunity within the CAR-T cell therapy space.
What are the main risks for GRCL?
Gracell Biotechnologies faces several key risks inherent to clinical-stage biopharmaceutical companies. These include the risk of clinical trial failures or delays, which could significantly impact the company's valuation and future prospects. Regulatory hurdles in China and other countries also pose a challenge, as the approval process for novel cell therapies can be lengthy and uncertain. Competition from established CAR-T cell therapy companies is another significant risk, as these companies have greater resources and experience. Additionally, the company faces financial risks associated with its high cash burn rate and reliance on third-party manufacturers.
What are the key factors to evaluate for GRCL?
Gracell Biotechnologies Inc. (GRCL) holds an AI score of 41/100 (low). Not financial advice.
How frequently does GRCL data refresh on this page?
GRCL prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GRCL's recent stock price performance?
Gracell Biotechnologies Inc. (GRCL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary FasTCAR and TruUCAR technology platforms. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GRCL overvalued or undervalued right now?
Valuing Gracell Biotechnologies Inc. (GRCL) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GRCL?
Before investing in Gracell Biotechnologies Inc. (GRCL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for GRCL, limiting the depth of insights.
- Financial data is based on publicly available information and may be subject to change.